AgingEarly Phase 1NCT07660601
Gait Adaptation Study
A Early Phase 1 study testing Gait Adaptation Training and Basic Physical Training in people with Aging, run by Rutgers, The State University of New Jersey at 1 site in United States.
Trial summary
This pilot study proposes a clinical trial to target treatment of sensorimotor and cognitive deficits in persons with Multiple Sclerosis (pwMS). The proposal has the potential to promote neuroplasticity and induce re-normalization in brain to muscle (cortico-muscular) connectivity (BMC) and within brain connectivity… Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Aging
- What is being tested?
- Gait Adaptation Training and Basic Physical Training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Jan 2025to 20 Jul 2028
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18 to 80 yrs Clinically definite MS diagnosis Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score >24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision
- Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and/or physical wellness such as brain injury, or stroke.
- Orthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse (new or returning neurological symptoms) or steroid treatment during the 30 days preceding enrollment
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Emily Peters, MS contact
United States1 site, 1 recruiting
- Recruiting
Stanley Bergen Building
Newark, New Jersey, 07107
Soha Saleh, 2014679455, soha.saleh@rutgers.edu
About this study
Official title: Integrative Training Approach for Inducing Neuroplasticity in Multiple Sclerosis
This pilot study proposes a clinical trial to target treatment of sensorimotor and cognitive deficits in persons with Multiple Sclerosis (pwMS). The proposal has the potential to promote neuroplasticity and induce re-normalization in brain to muscle (cortico-muscular) connectivity (BMC) and within brain connectivity via an integrative training approach. Preliminary data and published work are available to inform specific aspects of the proposed trial, along with the general rationale for exploring the suggested rehabilitation approach. However, there is a gap in research on the effects of training that uses the proposed approach via a clinical trial (of any phase) in pwMS to support the rationale for exploring the suggested rehabilitation training approach. Moreover, there is no pilot data on the training itself in the same population. This study will examine the behavioral deficits and neural characteristics in children with MS and two other related conditions (Myelin Oligodendrocyte Glycoprotein (MOG) and Nueromyelitis Optica Spectrum Disorder (NMOSD)) to understand if they would benefit from rehabilitation training conditions tested in aims 1 and 2. The overall long term goal is to improve rehabilitation training conditions for both adults and children with MS.
Read the detailed description
Multiple sclerosis (MS) is a neurological disorder that affects nearly 1 million adults in the United States (Wallin, Culpepper et al. 2019). Mobility and cognitive dysfunction are highly prevalent and debilitating consequences of MS, whereby upwards of 90% of patients present with mobility disability and upwards of 65% of patients demonstrate cognitive impairment (Chiaravalloti and DeLuca 2008, van Asch 2011, Chiaravalloti, Genova et al. 2015). Mobility and cognitive disability tend to co-occur in pwMS (i.e., cognitive-motor coupling), perhaps based on damage to neural substrates that are important for both domains of functioning (Benedict, Holtzer et al. 2011) (e.g., disruptions in the central nervous system (CNS) connectivity (Janssen, Boster et al. 2013, Wojtowicz, Mazerolle et al. 2014, Sbardella, Tona et al. 2015, Neva, Lakhani et al. 2016, Meijer, Eijlers et al. 2017, Saleh, Sandroff et al. 2018, van Geest, Douw et al. 2018, Chaves, Wallack et al. 2019, Hoxha, Glassen et al. 2019). Alarmingly, MS-related mobility and cognitive disability are both poorly managed with pharmacotherapy (DeLuca, Chiaravalloti et al. 2020). This underscores the importance of rehabilitation as an approach to managing MS-related mobility and cognitive dysfunction.
One particularly promising approach for rehabilitating MS-related mobility and cognitive dysfunction involves gait adaptability training (GAT, i.e., navigating real-world environments using precision stepping and obstacle avoidance) using mixed/augmented reality. Gait adaptability is inherently involved in most activities of daily living, where interaction with the physical environment requires proactive and reactive gait adaptations (Weerdesteyn, Hollands et al. 2018). GAT repeatedly and simultaneously trains mobility and cognitive processes and progressively increases in difficulty over time, leading to adaptations in both functions. This is supported by preliminary evidence of GAT-related improvements in mobility and cognition in neurological populations (van Ooijen, Heeren et al. 2015, Lau, Regis et al. 2022), including one recent clinical trial of virtual reality, dual-task treadmill training that involved some elements of gait adaptability that reported improvements in both mobility and cognition in pwMS (Hsieh, Mirelman et al. 2020, Galperin, Mirelman et al. 2022). However, there have been no trials of GAT, per se, on mobility and cognition in MS to date.
Of further importance, GAT research, in general, has not focused on restoring mobility and cognitive functioning in those who present with impairments in both mobility and cognition. Such research introduces the risk of ceiling effects and does not focus on the population presenting with the problems being studied, limiting inferences of treatment or restoration of function. Moreover, GAT research has not examined intervention effects on shared neural substrates of co-occurring, MS-related mobility and cognitive disability for establishing such an approach as a neuroplasticity-inducing behavior. Indeed, we have hypothesized that the neural processing and integration of multisensory inputs required for the regulation of physiological systems during acute walking becomes more efficient over time with ongoing, repeated, and progressively more challenging bouts of walking (i.e., GAT), resulting in adaptations in mobility and cognition, based on proximal adaptations in CNS connectivity (Sandroff, Motl et al. 2018). By extension, enhancing the multisensorial experience of walking with GAT should maximize adaptations in CNS connectivity, mobility, and cognition in pwMS (Sandroff, Motl et al. 2018). This proposal positions GAT as an innovative rehabilitative approach for enhancing the multisensorial demands of walking for eliciting meaningful mobility, cognitive, and neural adaptations in pwMS-related mobility and cognitive impairment, thus overcoming two major limitations associated with the rigor of the prior research.
Our preliminary EEG data suggest that avoiding obstacles during walking (i.e., gait adaptability) is associated with abnormal CNS (within-brain) effective connectivity (EC) in networks that are critical for mobility and cognition and in brain-to-muscle connectivity (BMC) in pwMS (Saleh, Glassen et al. 2020). This suggests that perhaps progressive, repetitive GAT might reverse such abnormalities and result in neurophysiological and functional benefits over time in pwMS who present with dysfunction. Thus, the proposed randomized controlled trial (RCT) in aim 1 \& 2 will examine the effects of GAT relative to an active control condition (basic physical training; BPT) on mobility and cognition, along with innovative endpoints of CNS connectivity and BMC in 30 pmMS participants. Indeed, including functional and neural endpoints is essential for providing initial empirical support for GAT as a biologically grounded, neuroplasticity-inducing, rehabilitative approach for managing the prevalent, debilitating, and co-occurring mobility and cognitive disability in MS.
In aim 1.a: Before recruitment and enrollment of MS participants, the mixed reality (GAT) training paradigm will be tested on group of 15 healthy subjects. The purpose is to determine the feasibility of the use of the mixed reality (MR) game with simultaneous EEG testing/recording. This goal of this pilot phase of aim 1 on healthy subjects is to confirm system's usability and comfort level by recording the Mixed Reality Concerns (MRC) questionnaire to determine trust in the MR system, the Virtual Embodiment Questionnaire (VEQ) to determine their comfort level with seeing an avatar represent themselves by copying their movement pattern, and the System Usability Survey (SUS) for overall usability of the software.
In aims 1.b \&2: We propose a single-blind, 2-arm RCT that compares the effects of a 12-session GAT intervention with an active control condition on functional and neuroimaging outcomes in 30 participants from three groups: 1) MS (n=30) with mobility and cognitive impairment. Upon satisfying inclusion/exclusion criteria, participants will undergo baseline mobility, cognitive, and neuroimaging outcome assessments. Following baseline testing, participants will be randomly assigned to either the intervention (GAT) or active control (BPT) condition. GAT will involve completing 12 training sessions using mixed reality (MR) over 4 weeks. BPT will involve completing 12 sessions of upper extremity movement and walking without purposeful gait adaptations over 4 weeks (i.e., walking alone). After the 4-week study period, participants will complete the same assessments as at baseline (i.e., follow-up) with blinded assessors.
GAT Intervention Condition: Participants will be trained for 12 sessions (4 weeks, 3 sessions per week) in a supervised paradigm that involves navigating an MR environment. This duration of GAT is consistent with research in neurological populations reporting mobility and cognitive improvements (Heeren, Van Ooijen et al. 2013, van Ooijen, Heeren et al. 2015, Timmermans, Roerdink et al. 2016, Hulzinga, Seuthe et al. 2022). The MR environment, built in Unity engine using the Mixed Reality Toolkit, will include externally cued targets that will appear as virtual objects. Participants are expected to perform precise real word activities like stacking books on shelves, picking up objects, etc (see Figure 1 in section 10). Microsoft HoloLens 2 MR goggles will be used to project these targets onto the real-world environment. For the current proposal, a library of 5 training applications during walking will be standardized across participants. Figure 1 shows an example of two applications. Within a given training session, the applications will be delivered in a predefined order across participants. The GAT prescription is primarily based on walking, but it involves integrative dual task activities like reaching, grasping, precision stepping. The progression in GAT training sessions will be individualized based on patients' performance and will involve increasing task difficulty. Specifically, the difficulty of the GAT tasks will progressively increase based on actual performance. Participants will wear motion sensors, and sensor information will be streamed and processed in real time to calculate performance accuracy and to adapt the game properties to provide a progression of training conditions, and to allow participants to practice the task more naturally and with high success. Once participants achieve a criterion of 80% accuracy on a given task, difficulty will incrementally increase upon the next administration of the task. Task difficulty will increase where GAT condition will require higher accuracy in precision stepping, providing higher number and faster rate of obstacle representations, and more stimulations in navigating the virtual environment.
BPT Condition: Training will take place with the same training dosage (duration) as the GAT condition; however, there will be no environmental or cognitive challenges applied. To control for upper extremity activities in the GAT training conditions (stacking objects, grasping, etc), BPT will include 10 minutes of practicing single upper extremity tasks while seated (reaching, grasping), followed by performing 30 minutes of single walking training in the gait lab without any cognitive demands.
In aim 3: We propose an exploratory study to measure the neural and behavioral characteristics of 40 children participants (4 groups with 10 children (13-17 years) with MS, MOG, NMOSD and gender- age- matched children with no neurological conditions). Upon satisfying inclusion/exclusion criteria, participants in this aim will attend a one visit session and complete the baseline measurements in aims 1\&2 detailed above (mobility, cognitive, and neuroimaging outcome assessments).
We plan to recruit 70 subjects [30 subjects (aim 1\&2); 40 subjects (aim 3)] in the pilot phase of the study. We decided on the sample size based on the feasibility to acquire enough pilot data to calculate effect size.
Aim 1a consists of one visit for ~2 hours. Aim 1b \& 2 consist of: three assessment visits ~3 hours each; and 12 training visits 1 hour each. A total of 21 hours over 12 weeks to complete study.
Aim 3 consists of one visit 3 hours long
Aim 1a Age 18 to 80 yrs Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score >24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision
Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and/or physical wellness such as brain injury, or stroke.
Orthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse or steroid treatment during the 30 days preceding enrollment
Aim 1b \& 2:
Inclusion Criteria Age 18 to 80 yrs Clinically definite MS diagnosis(Thompson et al, 2018) Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score >24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision
Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and/or physical wellness such as brain injury, or stroke.
Orthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse (new or returning neurological symptoms) or steroid treatment during the 30 days preceding enrollment
Aim 3 (* applicable to controls):
General criteria will be reviewed by RC and PI. The medical report and/or list of medications will be reviewed by Co-PI, a Neurologist.
Inclusion Criteria:
Pediatric Onset Multiple Sclerosis (POMS) diagnosed according to the most recent diagnostic criteria Or MOG or NMOSD MS Age 13 to 17 yrs* Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test for children (Salvador, Moura et al. 2019) with score >31 out of max score of 37 Self report normal or corrected-to-normal vision*
Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation * Neurological disorders (other than POMS, MOG, and NMOSD) that may affect cognition, balance or mobility, for example brain injury, stroke, epilepsy, autism, etc.
Orthopedic injuries neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study
Aim 1b and Aim 2b involve testing GAT vs BPT. GAT Intervention Condition: Participants will be trained for 12 sessions (4 weeks, 3 sessions per week) in a supervised paradigm in the GAIT lab at SHP, Rutgers RBHS. This duration of GAT is consistent with research in neurological populations reporting mobility and cognitive improvements [21], [109-111]. The VR training is programmed to allow training pwMS to walk while stepping on tracks, avoiding obstacles, picking up grocery items in a virtual environment, etc. (see Figure 4). The RW conditions are designed based on the FALLS [112]training condition and include slalom walking, steps, and obstacle avoidance (see Figure 5). A similar training setup has been implemented in stroke research and improving OA and Stroop task success rates[17]. We note that the cognitive challenges incorporated with GAT approximate those of the highly successful APT cognitive rehabilitation paradigm[113]. As GAT focuses on increasing the accuracy and speed of responding to environmental challenges that occur in the real world, the training stimulus will not progress in terms of walking speed across sessions. Regarding the progression of environmental challenges, GAT will require progressively higher accuracy in precision stepping, providing a higher number and faster rate of obstacle representations, and more stimulations in navigating the virtual environment. If a participant misses a given training session, a make-up session will be scheduled. If a participant misses multiple sessions, they will have up to 6-weeks to complete the 4-week training paradigm. Only cases where participants attend ≥10 of the 12 possible sessions will be included in the completers analysis.
BPT is designed based on conventional walking training where there is no innovative component in training conditions.
Aim 3 is a single session arm of the study where the independent variables are the subject groups that we will compare in terms of physical and cognitive function, and neurophysiology assessments (pediatric MS, NMOSD, MOG, and HC).
Aim 1a. - System user experience Mixed Reality Concerns (MRC) questionnaire to determine trust in the MR system, the Virtual Embodiment Questionnaire (VEQ) to determine subjects' comfort level with seeing an avatar represent themselves by copying their movement pattern, and the System Usability Survey (SUS) for overall usability of the software.
- Neurophysiology measures
- Resting-state brain connectivity
- EEG activity during task
Aim 1b \& 2 outcomes: A battery of outcome assessment will include evaluation of disability, physical function, cognitive function, and neurophysiology measures, see list below.
Disability
- Expanded Disability Status Score- EDSS (Kurtzke 1983)
- MS functional composite (MSFC)
Physical Function
- 25ftWT, primary outcome
- Dynamic Gait Index (DGI), primary outcome
- 6 min walking test (endurance test)
- Cardiovascular measure (resting heart rate) Cognitive Function BICAMS- Brief International Assessment for MS Neurophysiology measures
- Resting-state brain connectivity 2. Computed Muscle Control- CMC during walking (EEG-EMG coherence)
Aim 3 outcomes: A battery of outcome assessment will include evaluation of physical function, cognitive function and neurophysiology measures, see table 1.
Physical Function
- 25ftWT, primary outcome
- Dynamic Gait Index (DGI), primary outcome
- 6 min walking test (endurance test)
- Cardiovascular measure (resting heart rate) Cognitive Function
- Brief neuropsychological battery for children which include selective reminding test, SDMT, trail making test, and Vocabulary test from the Wechsler Intelligence Scale for children [brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis]
Neurophysiology measures
- Resting-state brain connectivity
- Computed Muscle Control- CMC during walking (EEG-EMG coherence)
- Conditions
- Aging
- Being tested
- Gait Adaptation Training, Basic Physical Training
- Keywords
- cognition, mobility, impairment, electrophysiology, gait, gait adaptation, daily living
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gait Adaptation TrainingBehavioural
GAT Intervention Condition: Participants will be trained for 12 sessions (4 weeks, 3 sessions per week) in a supervised paradigm that involves navigating an MR environment. This duration of GAT is consistent with research in neurological populations reporting mobility and cognitive improvements. The MR environment, built in Unity engine using the Mixed Reality Toolkit, will include externally cued targets that will appear as virtual objects. Participants are expected to perform precise real word activities like stacking books on shelves, picking up objects, etc (see Figure 1 in section 10). Microsoft HoloLens 2 MR goggles will be used to project these targets onto the real-world environment. For the current proposal, a library of 5 training applications during walking will be standardized across participants. Figure 1 shows an example of two applications.
Basic Physical TrainingBehavioural
BPT Condition: Training will take place with the same training dosage (duration) as the GAT condition; however, there will be no environmental or cognitive challenges applied. To control for upper extremity activities in the GAT training conditions (stacking objects, grasping, etc), BPT will include 10 minutes of practicing single upper extremity tasks while seated (reaching, grasping), followed by performing 30 minutes of single walking training in the gait lab without any cognitive demands.
| Study group | Role | What they receive |
|---|---|---|
| experimental group | Experimental | A group of persons with MS will be randomized to receive GAT or BPT interventions Receives: Behavioral: Gait Adaptation Training |
| control group | Active comparator | Persons with MS will enroll in training that involves basic physical training. Receives: Behavioral: Basic Physical Training |
What is being measured
The primary outcome is the main question the study is designed to answer.
walking speed
25ftWT
Measured: Baseline and after 4 weeks of training and after 4 weeks of the end of training
Dynamic Gait Index (DGI)
assessments of gait
Measured: Baseline and after 4 weeks of training and after 4 weeks of the end of training
Resting-state brain connectivity
Measured: Baseline and after 4 weeks of training and after 4 weeks of the end of training
brain-muscle coherence
Measured: Baseline and after 4 weeks of training and after 4 weeks of the end of training
Secondary outcomes (3)
6 min walking test
endurance test
Measured: Baseline and after 4 weeks of training and after 4 weeks of the end of training
Cardiovascular measure
resting heart rate
Measured: Baseline and after 4 weeks of training and after 4 weeks of the end of training
congition
BICAMS- Brief International Assessment for MS
Measured: Baseline and after 4 weeks of training and after 4 weeks of the end of training
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start31 Jan 2025
- Primary completion20 May 2028 (estimated)
- Study completion20 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- single-blind, 2-arm RCT that compares the effects of a 12-session GAT intervention with an active control condition on functional and neuroimaging outcomes in 30 participant
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rutgers, The State University of New Jersey
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Soha Saleh, PhD, Rutgers, The State University of New Jersey
- Investigators
- Soha Saleh, PhD, Principal investigator, Rutgers University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07660601
- Sponsor's protocol ID
- Pro2024001093
- Status last verified
- Jun 2026
- First submitted
- 11 May 2026
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Integrative Training Approach for Inducing Neuroplasticity in Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07660601
- Acronym / sponsor ID
- Pro2024001093
- Conditions
- Aging
- Keywords
- cognition, mobility, impairment, electrophysiology, gait, gait adaptation, daily living
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Rutgers, The State University of New JerseyUniversity, hospital or other
- Study start
- 31 Jan 2025 (actual)
- Primary completion
- 20 May 2028 (estimated)
- Study completion
- 20 Jul 2028 (estimated)
- First posted
- 22 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot study proposes a clinical trial to target treatment of sensorimotor and cognitive deficits in persons with Multiple Sclerosis (pwMS). The proposal has the potential to promote neuroplasticity and induce re-normalization in brain to muscle (cortico-muscular) connectivity (BMC) and within brain connectivity via an integrative training approach. Preliminary data and published work are available to inform specific aspects of the proposed trial, along with the general rationale for exploring the suggested rehabilitation approach. However, there is a gap in research on the effects of training that uses the proposed approach via a clinical trial (of any phase) in pwMS to support the rationale for exploring the suggested rehabilitation training approach. Moreover, there is no pilot data on the training itself in the same population. This study will examine the behavioral deficits and neural characteristics in children with MS and two other related conditions (Myelin Oligodendrocyte Glycoprotein (MOG) and Nueromyelitis Optica Spectrum Disorder (NMOSD)) to understand if they would benefit from rehabilitation training conditions tested in aims 1 and 2. The overall long term goal is to improve rehabilitation training conditions for both adults and children with MS.
Detailed description
Multiple sclerosis (MS) is a neurological disorder that affects nearly 1 million adults in the United States (Wallin, Culpepper et al. 2019). Mobility and cognitive dysfunction are highly prevalent and debilitating consequences of MS, whereby upwards of 90% of patients present with mobility disability and upwards of 65% of patients demonstrate cognitive impairment (Chiaravalloti and DeLuca 2008, van Asch 2011, Chiaravalloti, Genova et al. 2015). Mobility and cognitive disability tend to co-occur in pwMS (i.e., cognitive-motor coupling), perhaps based on damage to neural substrates that are important for both domains of functioning (Benedict, Holtzer et al. 2011) (e.g., disruptions in the central nervous system (CNS) connectivity (Janssen, Boster et al. 2013, Wojtowicz, Mazerolle et al. 2014, Sbardella, Tona et al. 2015, Neva, Lakhani et al. 2016, Meijer, Eijlers et al. 2017, Saleh, Sandroff et al. 2018, van Geest, Douw et al. 2018, Chaves, Wallack et al. 2019, Hoxha, Glassen et al. 2019). Alarmingly, MS-related mobility and cognitive disability are both poorly managed with pharmacotherapy (DeLuca, Chiaravalloti et al. 2020). This underscores the importance of rehabilitation as an approach to managing MS-related mobility and cognitive dysfunction.
One particularly promising approach for rehabilitating MS-related mobility and cognitive dysfunction involves gait adaptability training (GAT, i.e., navigating real-world environments using precision stepping and obstacle avoidance) using mixed/augmented reality. Gait adaptability is inherently involved in most activities of daily living, where interaction with the physical environment requires proactive and reactive gait adaptations (Weerdesteyn, Hollands et al. 2018). GAT repeatedly and simultaneously trains mobility and cognitive processes and progressively increases in difficulty over time, leading to adaptations in both functions. This is supported by preliminary evidence of GAT-related improvements in mobility and cognition in neurological populations (van Ooijen, Heeren et al. 2015, Lau, Regis et al. 2022), including one recent clinical trial of virtual reality, dual-task treadmill training that involved some elements of gait adaptability that reported improvements in both mobility and cognition in pwMS (Hsieh, Mirelman et al. 2020, Galperin, Mirelman et al. 2022). However, there have been no trials of GAT, per se, on mobility and cognition in MS to date.
Of further importance, GAT research, in general, has not focused on restoring mobility and cognitive functioning in those who present with impairments in both mobility and cognition. Such research introduces the risk of ceiling effects and does not focus on the population presenting with the problems being studied, limiting inferences of treatment or restoration of function. Moreover, GAT research has not examined intervention effects on shared neural substrates of co-occurring, MS-related mobility and cognitive disability for establishing such an approach as a neuroplasticity-inducing behavior. Indeed, we have hypothesized that the neural processing and integration of multisensory inputs required for the regulation of physiological systems during acute walking becomes more efficient over time with ongoing, repeated, and progressively more challenging bouts of walking (i.e., GAT), resulting in adaptations in mobility and cognition, based on proximal adaptations in CNS connectivity (Sandroff, Motl et al. 2018). By extension, enhancing the multisensorial experience of walking with GAT should maximize adaptations in CNS connectivity, mobility, and cognition in pwMS (Sandroff, Motl et al. 2018). This proposal positions GAT as an innovative rehabilitative approach for enhancing the multisensorial demands of walking for eliciting meaningful mobility, cognitive, and neural adaptations in pwMS-related mobility and cognitive impairment, thus overcoming two major limitations associated with the rigor of the prior research.
Our preliminary EEG data suggest that avoiding obstacles during walking (i.e., gait adaptability) is associated with abnormal CNS (within-brain) effective connectivity (EC) in networks that are critical for mobility and cognition and in brain-to-muscle connectivity (BMC) in pwMS (Saleh, Glassen et al. 2020). This suggests that perhaps progressive, repetitive GAT might reverse such abnormalities and result in neurophysiological and functional benefits over time in pwMS who present with dysfunction. Thus, the proposed randomized controlled trial (RCT) in aim 1 \& 2 will examine the effects of GAT relative to an active control condition (basic physical training; BPT) on mobility and cognition, along with innovative endpoints of CNS connectivity and BMC in 30 pmMS participants. Indeed, including functional and neural endpoints is essential for providing initial empirical support for GAT as a biologically grounded, neuroplasticity-inducing, rehabilitative approach for managing the prevalent, debilitating, and co-occurring mobility and cognitive disability in MS.
In aim 1.a: Before recruitment and enrollment of MS participants, the mixed reality (GAT) training paradigm will be tested on group of 15 healthy subjects. The purpose is to determine the feasibility of the use of the mixed reality (MR) game with simultaneous EEG testing/recording. This goal of this pilot phase of aim 1 on healthy subjects is to confirm system's usability and comfort level by recording the Mixed Reality Concerns (MRC) questionnaire to determine trust in the MR system, the Virtual Embodiment Questionnaire (VEQ) to determine their comfort level with seeing an avatar represent themselves by copying their movement pattern, and the System Usability Survey (SUS) for overall usability of the software.
In aims 1.b \&2: We propose a single-blind, 2-arm RCT that compares the effects of a 12-session GAT intervention with an active control condition on functional and neuroimaging outcomes in 30 participants from three groups: 1) MS (n=30) with mobility and cognitive impairment. Upon satisfying inclusion/exclusion criteria, participants will undergo baseline mobility, cognitive, and neuroimaging outcome assessments. Following baseline testing, participants will be randomly assigned to either the intervention (GAT) or active control (BPT) condition. GAT will involve completing 12 training sessions using mixed reality (MR) over 4 weeks. BPT will involve completing 12 sessions of upper extremity movement and walking without purposeful gait adaptations over 4 weeks (i.e., walking alone). After the 4-week study period, participants will complete the same assessments as at baseline (i.e., follow-up) with blinded assessors.
GAT Intervention Condition: Participants will be trained for 12 sessions (4 weeks, 3 sessions per week) in a supervised paradigm that involves navigating an MR environment. This duration of GAT is consistent with research in neurological populations reporting mobility and cognitive improvements (Heeren, Van Ooijen et al. 2013, van Ooijen, Heeren et al. 2015, Timmermans, Roerdink et al. 2016, Hulzinga, Seuthe et al. 2022). The MR environment, built in Unity engine using the Mixed Reality Toolkit, will include externally cued targets that will appear as virtual objects. Participants are expected to perform precise real word activities like stacking books on shelves, picking up objects, etc (see Figure 1 in section 10). Microsoft HoloLens 2 MR goggles will be used to project these targets onto the real-world environment. For the current proposal, a library of 5 training applications during walking will be standardized across participants. Figure 1 shows an example of two applications. Within a given training session, the applications will be delivered in a predefined order across participants. The GAT prescription is primarily based on walking, but it involves integrative dual task activities like reaching, grasping, precision stepping. The progression in GAT training sessions will be individualized based on patients' performance and will involve increasing task difficulty. Specifically, the difficulty of the GAT tasks will progressively increase based on actual performance. Participants will wear motion sensors, and sensor information will be streamed and processed in real time to calculate performance accuracy and to adapt the game properties to provide a progression of training conditions, and to allow participants to practice the task more naturally and with high success. Once participants achieve a criterion of 80% accuracy on a given task, difficulty will incrementally increase upon the next administration of the task. Task difficulty will increase where GAT condition will require higher accuracy in precision stepping, providing higher number and faster rate of obstacle representations, and more stimulations in navigating the virtual environment.
BPT Condition: Training will take place with the same training dosage (duration) as the GAT condition; however, there will be no environmental or cognitive challenges applied. To control for upper extremity activities in the GAT training conditions (stacking objects, grasping, etc), BPT will include 10 minutes of practicing single upper extremity tasks while seated (reaching, grasping), followed by performing 30 minutes of single walking training in the gait lab without any cognitive demands.
In aim 3: We propose an exploratory study to measure the neural and behavioral characteristics of 40 children participants (4 groups with 10 children (13-17 years) with MS, MOG, NMOSD and gender- age- matched children with no neurological conditions). Upon satisfying inclusion/exclusion criteria, participants in this aim will attend a one visit session and complete the baseline measurements in aims 1\&2 detailed above (mobility, cognitive, and neuroimaging outcome assessments).
We plan to recruit 70 subjects [30 subjects (aim 1\&2); 40 subjects (aim 3)] in the pilot phase of the study. We decided on the sample size based on the feasibility to acquire enough pilot data to calculate effect size.
Aim 1a consists of one visit for ~2 hours. Aim 1b \& 2 consist of: three assessment visits ~3 hours each; and 12 training visits 1 hour each. A total of 21 hours over 12 weeks to complete study.
Aim 3 consists of one visit 3 hours long
Aim 1a Age 18 to 80 yrs Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score >24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision
Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and/or physical wellness such as brain injury, or stroke.
Orthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse or steroid treatment during the 30 days preceding enrollment
Aim 1b \& 2:
Inclusion Criteria Age 18 to 80 yrs Clinically definite MS diagnosis(Thompson et al, 2018) Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score >24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision
Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and/or physical wellness such as brain injury, or stroke.
Orthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse (new or returning neurological symptoms) or steroid treatment during the 30 days preceding enrollment
Aim 3 (* applicable to controls):
General criteria will be reviewed by RC and PI. The medical report and/or list of medications will be reviewed by Co-PI, a Neurologist.
Inclusion Criteria:
Pediatric Onset Multiple Sclerosis (POMS) diagnosed according to the most recent diagnostic criteria Or MOG or NMOSD MS Age 13 to 17 yrs* Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test for children (Salvador, Moura et al. 2019) with score >31 out of max score of 37 Self report normal or corrected-to-normal vision*
Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation * Neurological disorders (other than POMS, MOG, and NMOSD) that may affect cognition, balance or mobility, for example brain injury, stroke, epilepsy, autism, etc.
Orthopedic injuries neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study
Aim 1b and Aim 2b involve testing GAT vs BPT. GAT Intervention Condition: Participants will be trained for 12 sessions (4 weeks, 3 sessions per week) in a supervised paradigm in the GAIT lab at SHP, Rutgers RBHS. This duration of GAT is consistent with research in neurological populations reporting mobility and cognitive improvements [21], [109-111]. The VR training is programmed to allow training pwMS to walk while stepping on tracks, avoiding obstacles, picking up grocery items in a virtual environment, etc. (see Figure 4). The RW conditions are designed based on the FALLS [112]training condition and include slalom walking, steps, and obstacle avoidance (see Figure 5). A similar training setup has been implemented in stroke research and improving OA and Stroop task success rates[17]. We note that the cognitive challenges incorporated with GAT approximate those of the highly successful APT cognitive rehabilitation paradigm[113]. As GAT focuses on increasing the accuracy and speed of responding to environmental challenges that occur in the real world, the training stimulus will not progress in terms of walking speed across sessions. Regarding the progression of environmental challenges, GAT will require progressively higher accuracy in precision stepping, providing a higher number and faster rate of obstacle representations, and more stimulations in navigating the virtual environment. If a participant misses a given training session, a make-up session will be scheduled. If a participant misses multiple sessions, they will have up to 6-weeks to complete the 4-week training paradigm. Only cases where participants attend ≥10 of the 12 possible sessions will be included in the completers analysis.
BPT is designed based on conventional walking training where there is no innovative component in training conditions.
Aim 3 is a single session arm of the study where the independent variables are the subject groups that we will compare in terms of physical and cognitive function, and neurophysiology assessments (pediatric MS, NMOSD, MOG, and HC).
Aim 1a. - System user experience Mixed Reality Concerns (MRC) questionnaire to determine trust in the MR system, the Virtual Embodiment Questionnaire (VEQ) to determine subjects' comfort level with seeing an avatar represent themselves by copying their movement pattern, and the System Usability Survey (SUS) for overall usability of the software.
- Neurophysiology measures
- Resting-state brain connectivity
- EEG activity during task
Aim 1b \& 2 outcomes: A battery of outcome assessment will include evaluation of disability, physical function, cognitive function, and neurophysiology measures, see list below.
Disability
- Expanded Disability Status Score- EDSS (Kurtzke 1983)
- MS functional composite (MSFC)
Physical Function
- 25ftWT, primary outcome
- Dynamic Gait Index (DGI), primary outcome
- 6 min walking test (endurance test)
- Cardiovascular measure (resting heart rate) Cognitive Function BICAMS- Brief International Assessment for MS Neurophysiology measures
- Resting-state brain connectivity 2. Computed Muscle Control- CMC during walking (EEG-EMG coherence)
Aim 3 outcomes: A battery of outcome assessment will include evaluation of physical function, cognitive function and neurophysiology measures, see table 1.
Physical Function
- 25ftWT, primary outcome
- Dynamic Gait Index (DGI), primary outcome
- 6 min walking test (endurance test)
- Cardiovascular measure (resting heart rate) Cognitive Function
- Brief neuropsychological battery for children which include selective reminding test, SDMT, trail making test, and Vocabulary test from the Wechsler Intelligence Scale for children [brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis]
Neurophysiology measures
- Resting-state brain connectivity
- Computed Muscle Control- CMC during walking (EEG-EMG coherence)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- single-blind, 2-arm RCT that compares the effects of a 12-session GAT intervention with an active control condition on functional and neuroimaging outcomes in 30 participant
| Arm | Type | Receives |
|---|---|---|
| experimental group | Experimental | Behavioral: Gait Adaptation TrainingA group of persons with MS will be randomized to receive GAT or BPT interventions |
| control group | Active comparator | Behavioral: Basic Physical TrainingPersons with MS will enroll in training that involves basic physical training. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18 to 80 yrs Clinically definite MS diagnosis Ability to attend to computer screen and follow instructions in English which will be assessed by MiniMental test requiring a participant to score >24 (out of 30 max score) Right-handed as determined by research diagnostic criteria of the Edinburgh Handedness Inventory (Oldfield 1971) Self report of normal or corrected-to-normal vision
- Exclusion Criteria Psychiatric disorders, only those requiring treatment because the medications may affect brain activation Neurological disorder that may affect cognition, balance, and/or physical wellness such as brain injury, or stroke.
- Orthopedic injuries or neuromuscular disorder that may affect balance or mobility Engagement in other cognitive or physical training program while enrolled in this study Ongoing relapse (new or returning neurological symptoms) or steroid treatment during the 30 days preceding enrollment
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gait Adaptation TrainingGAT Intervention Condition: Participants will be trained for 12 sessions (4 weeks, 3 sessions per week) in a supervised paradigm that involves navigating an MR environment. This duration of GAT is consistent with research in neurological populations reporting mobility and cognitive improvements. The MR environment, built in Unity engine using the Mixed Reality Toolkit, will include externally cued targets that will appear as virtual objects. Participants are expected to perform precise real word activities like stacking books on shelves, picking up objects, etc (see Figure 1 in section 10). Microsoft HoloLens 2 MR goggles will be used to project these targets onto the real-world environment. For the current proposal, a library of 5 training applications during walking will be standardized across participants. Figure 1 shows an example of two applications. | Behavioural | experimental group |
| Basic Physical TrainingBPT Condition: Training will take place with the same training dosage (duration) as the GAT condition; however, there will be no environmental or cognitive challenges applied. To control for upper extremity activities in the GAT training conditions (stacking objects, grasping, etc), BPT will include 10 minutes of practicing single upper extremity tasks while seated (reaching, grasping), followed by performing 30 minutes of single walking training in the gait lab without any cognitive demands. | Behavioural | control group |
Primary outcome
walking speed
Time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training
25ftWT
Dynamic Gait Index (DGI)
Time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training
assessments of gait
Resting-state brain connectivity
Time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training
brain-muscle coherence
Time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training
3 secondary outcomes
6 min walking test
Time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training
Cardiovascular measure
Time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training
congition
Time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Aging
RecruitingPhase 3
Vibegron for ENergy Thinking and Resilience in Aging
Obesity
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Cerebello-Cortical Connectivity and Balance Adaptation in Younger and Older Adults
Aging, Postural Balance
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
Not yet recruiting
Wearable Ankle Power Training (WearAPT) for Enhanced Mobility in Aging
Sedentary Behavior / Physical Inactivity, Aged
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Emily Peters, MS contact
Soha Saleh, PhD principal investigator
Rutgers University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Gait Adaptation Training and Basic Physical Training in people with Aging, run by Rutgers, The State University of New Jersey at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Soha Saleh, PhD (9739720472, soha.saleh@rutgers.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
walking speed (time frame: Baseline and after 4 weeks of training and after 4 weeks of the end of training). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.